Key facts
- This page summarizes Patrick Lamy's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Jan 2025, 20:43.
Patrick Lamy - 31 Dec 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- Senior VP, Commercial Strategy
- Issuer ticker
- AKRO
- Reported as of
- 31 Dec 2024
- Net transaction value
- -$201,063
- SEC form
- 4
- Accepted by SEC
- 29 Jan 2025, 20:43:28 UTC
- Prior SEC filing
- 18 Dec 2024
- Next SEC filing
- 05 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Young, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lamy filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 29 Jan 2025.
Change
- Previous filing in this sequence was filed on 18 Dec 2024.
- Current net transaction value: -$201,063.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKRO
transaction
Common Stock
Award
- Transaction value
- $4,607
- Shares
- +234
- Change %
- +0.68%
- Price
- $19.69
- Shares after
- 34,492
- Date
- 31 Dec 2024
- Ownership
- Direct
- Footnotes
- F1, F2
AKRO
transaction
Common Stock
Options Exercise
- Transaction value
- $79,480
- Shares
- +4,000
- Change %
- +12%
- Price
- $19.87
- Shares after
- 38,492
- Date
- 27 Jan 2025
- Ownership
- Direct
- Footnotes
- F3
AKRO
transaction
Common Stock
Sale
- Transaction value
- $285,150
- Shares
- -5,000
- Change %
- -13%
- Price
- $57.03
- Shares after
- 33,492
- Date
- 27 Jan 2025
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -4,000
- Change %
- -4.8%
- Price
- $0.000000
- Shares after
- 79,182
- Date
- 27 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 83,182
- Exercise price
- $19.87
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Mr. Lamy is voluntarily reporting the acquisition of these shares on December 31, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
Footnote F2
In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on July 1, 2024.
Footnote F3
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 28, 2024, previously adopted by the Reporting Person.
Footnote F4
This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023.